SF4875

Purpose

• To modify how Minnesota handles medical cannabis endorsements for cannabis businesses, with the aim of expanding oversight, tightening steps for patient-specific distribution, and clarifying who can approve and supervise distribution.

Main Provisions

• Endorsement types created and defined
  • Cultivation endorsement: Allows a license holder to grow medical cannabis, sell flower to other medical cannabis entities, and perform other office-approved actions.
  • Processor endorsement: Allows purchasing of medical cannabis flower, cannabinoid products, hemp parts, and hemp concentrate; making cannabis and hemp concentrates (including some hemp concentrates with higher delta-9 THC); manufacturing and labeling medical cannabinoid products; and other office-approved actions.
  • Retail endorsement: Allows selling and distributing medical cannabis flower, cannabinoid products, and related paraphernalia; requires at least one trained employee (medical cannabis consultant with an office certificate or a licensed pharmacist) or a contracted/employed pharmacist to provide final authorization; requires verification and compliance steps before distribution.
• Distribution and verification requirements
  • Before distributing to someone in the registry, staff must verify enrollment, confirm identity and eligibility (patient, designated caregiver, or parent/legal guardian/spouse), ensure the patient had a consultation with a certified medical cannabis consultant or licensed pharmacist, apply a patient-specific dosage label, and provide required information.
  • Retail endorsement holders may not deliver to registry-enrolled individuals unless they also hold a cannabis delivery service license.
• Final approval and patient consultation
  • Only a pharmacist (licensed under chapter 151) or a certified medical cannabis consultant employed by a retailer endorsement holder may give final approval for distribution.
  • Consultations must consider the patient’s needs, including first-time purchases, changes in administration method, or changes in dosage; consultations can occur remotely via telemedicine as long as identity and privacy protections are maintained.
• Testing and safety
  • Requirements apply to testing and labeling to ensure safety, potency, and consistency before products are distributed to patients.
• Delivery and telemedicine
  • Delivery-specific provisions and the option for remote consultations expand access while maintaining oversight.

Significant Changes to Existing Law

• Introduces new endorsement categories (cultivation, processor, retailer) with specific authorizations and duties.
• Ties retailer endorsements to the need for a licensed pharmacist or certified medical cannabis consultant for final distribution approval.
• Adds explicit patient verification, dosage labeling, and pre-distribution consultation requirements.
• Replaces or strengthens the prior framework by requiring safety testing visibility and a formal labeling standard before distribution.
• Establishes or clarifies a delivery license requirement for any cannabis delivery activity by retailers.
• Allows telemedicine-based consultations for patient care and dosage determinations, expanding access while preserving oversight.

Impact and Stakeholders (Summary)

• Affects cannabis license holders (cultivators, processors, retailers) who will need appropriate endorsements and staff with specialized training.
• Impacts patients enrolled in the registry by requiring documented consultations, labeled dosages, and verified distributions.
• Involves pharmacists and medical cannabis consultants as key decision-makers for final distribution approval.
• Could expand access to medical cannabis through delivery services and remote consultations, while increasing verification and safety measures.

Relevant Terms - medical cannabis endorsement - cultivation endorsement - processor endorsement - retailer endorsement - cannabis license holder - medical cannabis flower - medical cannabinoid products - hemp plant parts - hemp concentrate - delta-9 tetrahydrocannabinol (delta-9 THC) - hemp concentrate > 0.3% THC by weight - industrial hemp - medical cannabis testing facility - registry program - patient - designated caregiver - parent legal guardian - spouse - medical cannabis consultant - licensed pharmacist (chapter 151) - office (the agency issuing endorsements) - distribution - patient-specific label - dosage requirements - final approval - telemedicine - secure videoconference/remote consultation - delivery service license